Molecular Profile Detail

Profile Name BRCA2 loss
Gene Variant Detail

BRCA2 loss (loss of function)

Relevant Treatment Approaches PARP Inhibitor (Pan) PARP-1 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRCA2 loss ovarian cancer predicted - sensitive APTO-253 Preclinical - Cell culture Actionable In a preclinical study, APTO-253 treatment resulted in decreased viability in BRCA2-deficient ovarian cancer cells in culture (PMID: 29626126). 29626126
BRCA2 loss colorectal cancer sensitive YU238259 Preclinical - Cell line xenograft Actionable In a preclinical study, YU238259 induced cytotoxicity in a human BRCA2-deficient colorectal cancer cell line in culture and slowed tumor growth in xenograft models (PMID: 26116172). 26116172
BRCA2 loss prostate cancer sensitive PARP Inhibitor (Pan) Olaparib Phase II Actionable In a Phase II clinical trial, 100% (7/7) of metastatic castration-resistant prostate cancer patients with BRCA2 loss demonstrated response to Lynparza (olaparib) treatment (PMID: 26510020). 26510020
BRCA2 loss ovary adenocarcinoma sensitive YU238259 Preclinical Actionable In a preclinical study, YU238259 demonstrated increased cytotoxicity compared to control in BRCA2-deficient ovarian adenocarcinoma cell lines in culture (PMID: 26116172). 26116172
BRCA2 loss colorectal cancer sensitive Etoposide + YU238259 Preclinical Actionable In a preclinical study, YU238259 and Eposin (etoposide) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172). 26116172
BRCA2 loss colorectal cancer sensitive Radiotherapy + YU238259 Preclinical Actionable In a preclinical study, YU238259 and radiotherapy synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172). 26116172
BRCA2 loss colorectal cancer sensitive PARP Inhibitor (Pan) Olaparib + YU238259 Preclinical - Cell culture Actionable In a preclinical study, YU238259 and Lynparza (olaparib) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172). 26116172
BRCA2 loss colorectal adenocarcinoma sensitive AZD6738 + Radiotherapy Preclinical - Cell culture Actionable In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line deficient for BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704). 28062704
BRCA2 loss pancreatic cancer sensitive PARP-1 Inhibitor NMS-P118 + Temozolomide Preclinical - Cell line xenograft Actionable In a preclinical study, NMS-P118 enhanced the effects of Temodar (temozolomide) in BRCA2-deficient pancreatic cancer xenograft models, demonstrating inhibition of tumor growth and a complete response in 50% (3/6) of the models (PMID: 26222319). 26222319
Clinical Trial Phase Therapies Title Recruitment Status
NCT02286687 Phase II Talazoparib Phase II Study of BMN 673 Recruiting